|Safety, activity, and immune correlates of anti–PD-1 antibody in cancer|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
|Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer|
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
|Pembrolizumab for the treatment of non–small-cell lung cancer|
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
|Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients|
RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ...
Nature 515 (7528), 563-567, 2014
|First-line crizotinib versus chemotherapy in ALK-positive lung cancer|
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
|First-line nivolumab in stage IV or recurrent non–small-cell lung cancer|
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
|First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer|
L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ...
New England Journal of Medicine 379 (23), 2220-2229, 2018
|AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer|
PA Jänne, JCH Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, ...
New England Journal of Medicine 372 (18), 1689-1699, 2015
|Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis|
DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ...
JAMA oncology 4 (12), 1721-1728, 2018
|Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase …|
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The lancet oncology 16 (3), 257-265, 2015
|Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer|
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004, 2015
|Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial|
SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ...
The Lancet Oncology 17 (7), 883-895, 2016
|Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology|
DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017
|Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study|
EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ...
Journal of Clinical Oncology 37 (28), 2518, 2019
|Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials …|
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ...
Journal of clinical oncology 35 (35), 3924, 2017
|Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study|
S Gettinger, L Horn, D Jackman, D Spigel, S Antonia, M Hellmann, ...
Journal of Clinical Oncology 36 (17), 1675-1684, 2018
|NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines|
DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ...
Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019
|COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study|
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
|Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations|
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ...
New England Journal of Medicine 383 (10), 931-943, 2020
|Non–small cell lung cancer, version 2.2013|
DS Ettinger, W Akerley, H Borghaei, AC Chang, RT Cheney, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 11 (6), 645-653, 2013